Ricky Goldwasser
Stock Analyst at Morgan Stanley
(4.11)
# 488
Out of 5,154 analysts
233
Total ratings
62.11%
Success rate
8.65%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNC Centene | Maintains: Equal-Weight | $38 → $45 | $43.65 | +3.09% | 15 | Mar 4, 2026 | |
| DOCS Doximity | Maintains: Overweight | $65 → $49 | $25.34 | +93.37% | 12 | Feb 6, 2026 | |
| UNH UnitedHealth Group | Maintains: Overweight | $411 → $409 | $286.48 | +42.77% | 21 | Jan 23, 2026 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $170 → $185 | $174.46 | +6.04% | 23 | Nov 11, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $283 → $306 | $269.67 | +13.47% | 17 | Jul 25, 2025 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $6.93 | +44.30% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $2.28 | +141.23% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $13.84 | -45.81% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $18.44 | -34.92% | 8 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $199.21 | -27.21% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $144.47 | +152.65% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $919.26 | -54.31% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $5.46 | +2,097.80% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $179.15 | +246.08% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $289.64 | +72.63% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $77.92 | +59.14% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $271.63 | +17.07% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $217.78 | -67.86% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $174.49 | +11.75% | 6 | Oct 21, 2020 |
Centene
Mar 4, 2026
Maintains: Equal-Weight
Price Target: $38 → $45
Current: $43.65
Upside: +3.09%
Doximity
Feb 6, 2026
Maintains: Overweight
Price Target: $65 → $49
Current: $25.34
Upside: +93.37%
UnitedHealth Group
Jan 23, 2026
Maintains: Overweight
Price Target: $411 → $409
Current: $286.48
Upside: +42.77%
Charles River Laboratories International
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $170 → $185
Current: $174.46
Upside: +6.04%
Labcorp Holdings
Jul 25, 2025
Maintains: Overweight
Price Target: $283 → $306
Current: $269.67
Upside: +13.47%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $6.93
Upside: +44.30%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $2.28
Upside: +141.23%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $13.84
Upside: -45.81%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $18.44
Upside: -34.92%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $199.21
Upside: -27.21%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $144.47
Upside: +152.65%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $919.26
Upside: -54.31%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $5.46
Upside: +2,097.80%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $179.15
Upside: +246.08%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $289.64
Upside: +72.63%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $77.92
Upside: +59.14%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $271.63
Upside: +17.07%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $217.78
Upside: -67.86%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $174.49
Upside: +11.75%